Skip to content

Remifentanil EC50 for suppressing cardiovascular responses of different menstrual cycle phases to a standardized noxious stimuli during Entropy-guided propofol anesthesia

Remifentanil EC50 for suppressing cardiovascular responses of different menstrual cycle phases to a standardized noxious stimuli during Entropy-guided propofol anesthesia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-RPC-17010909
Enrollment
Unknown
Registered
2017-03-18
Start date
2017-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary infertility

Interventions

follicle phase group:Remifentanil target concentration
luteal phase group:Remifentanil target concentration

Sponsors

Women's Hospital, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Adult fertile women, aged 18-40 yr, ASA physical status I-II, with regular menstrual cycles (a regular cycle was defined as lasting 23-35 days with no variations more than 2 days)(21), receiving general anesthesia for elective gynaecological laparoscopy surgery were enrolled.

Exclusion criteria

Exclusion criteria: BMI33; pregnant; less than two months from termination of pregnancy;receiving hormones or medications affecting ovulation in 6 weeks before surgery;(16) chronic or acute (within 48 h) intake of psychotropic drugs; use of CNS-active medication or alcoholism or opioids;presence of any disease of cardiac ,pulmonary,hepatic, renal, or neurological. In addition ,patients were also excluded if local anesthetics, atropine, epinephrine, or other vaso-active medications were used during the study.

Design outcomes

Primary

MeasureTime frame
female sex hormone;EC50 of remifentanil;SPI;Entropy index;Blood pressure;Heart rate;

Countries

China

Contacts

Public ContactYanhong Zhou

Women's Hospital, Zhejiang University

yanhong19861116@126.com+86 18806523402

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026